Assessing oncology providers attitudes and practices toward nonformulary drugs and mapping current obstacles in Saudi Arabia

• Published in: Saudi pharmaceutical journal 2023-12, Vol.31 (12), p.101840-101840, Article 101840
• Main Authors: Alkhudair, Nora, Alhifany, Abdullah A., Alsubaie, Basha, Alshubaiki, Leena, Alrajhi, Abdullah M., alnuhait, Mohammed
• Format: Article
• Language: English
• Subjects: Formulary; Healthcare; Medications; Oncology; Pharmacists; Physicians
• ISSN: 1319-0164; 2213-7475
• DOI: 10.1016/j.jsps.2023.101840

Formulary drug list is a continually updated list of medications routinely stocked by hospitals and other healthcare facilities and deemed effective, safe, and cost saving. Non-formulary drug (NFD) refers to medications not on the formulary, due to cost or lack of clinical data. This study aimed to examine the processing of NFD requests by oncology providers (OPs) in Saudi Arabia. A cross-sectional survey in Saudi oncology centers gathered perspectives of healthcare practitioners, mainly oncology pharmacists and physicians, on NFDs and request processes, aiming to understand variations, reasons for NFDs, and suggestions for an improved, unified NFDs request algorithm. A total of 93 physicians and pharmacists responded, 57 % were pharmacists, 43 % were physicians, and 94.6 % worked in the governmental sector. Around 31.2 % reported that it takes one week to receive a decision on their NFD request, while 28 % reported it takes two weeks to one month. Furthermore, 35.5 % of participants reported that the complete NFD process, from the initial order placement to the receipt of medications, spans a duration of 2–4 months, while 8.6 % noted a longer duration exceeding six months. The participants reported that the most common obstacles while requesting NFD were procurement delays and lengthy processing times. Additionally, 26.9 % agreed that formulary restrictions hindered medical care and 40.3 % reported delays in patient care. While 33.8 % were forced to use fewer effective options, and 22.1 % referred patients to palliative care. The current practice of NFDs has negative consequences on cancer patient outcomes due to delays in patient care or the use of less effective drugs. Thus, we recommend having a national NFD access program.